IDH1 and central nervous system cancer: Treatment of mice with the selective IDH1R132H inhibitor AG-5198 led to marked reduction of intracellular 2-HG levels and delayed the growth of IDH1-mut TS603 glioma xenografts (* p = 0.015, two-tailed t-test), without impairing IDH1-wt TS516 xenografts [27].